Markowitz Joseph, Wang Jiang, Vangundy Zach, You Jia, Yildiz Vedat, Yu Lianbo, Foote Isaac P, Branson Owen E, Stiff Andrew R, Brooks Taylor R, Biesiadecki Brandon, Olencki Thomas, Tridandapani Susheela, Freitas Michael A, Papenfuss Tracey, Phelps Mitch A, Carson William E
Moffitt Cancer Center Department of Cutaneous Oncology, Tampa, United States.
Department of Oncologic Sciences USF Morsani School of Medicine, Tampa, United States.
Sci Rep. 2017 Nov 13;7(1):15424. doi: 10.1038/s41598-017-14970-0.
Myeloid derived suppressor cells (MDSC) produce nitric oxide (NO) and inhibit dendritic cell (DC) immune responses in cancer. DCs present cancer cell antigens to CD4 T cells through Jak-STAT signal transduction. In this study, NO donors (SNAP and DETA-NONOate) inhibited DC antigen presentation. As expected, MDSC isolated from peripheral blood mononuclear cells (PBMC) from cancer patients produced high NO levels. We hypothesized that NO producing MDSC in tumor-bearing hosts would inhibit DC antigen presentation. Antigen presentation from DCs to CD4 T cells (T cell receptor transgenic OT-II) was measured via a [H]-thymidine incorporation proliferation assay. MDSC from melanoma tumor models decreased the levels of proliferation more than pancreatic cancer derived MDSC. T cell proliferation was restored when MDSC were treated with inhibitors of inducible nitric oxide synthase (L-NAME and NCX-4016). A NO donor inhibited OT II T cell receptor recognition of OT II specific tetramers, thus serving as a direct measure of NO inhibition of antigen presentation. Our group has previously demonstrated that STAT1 nitration also mediates MDSC inhibitory effects on immune cells. Therefore, a novel liquid chromatography-tandem mass spectrometry assay demonstrated that nitration of the STAT1-Tyr701 occurs in PBMC derived from both pancreatic cancer and melanoma patients.
髓源性抑制细胞(MDSC)产生一氧化氮(NO)并抑制癌症中树突状细胞(DC)的免疫反应。DC通过Jak-STAT信号转导将癌细胞抗原呈递给CD4 T细胞。在本研究中,NO供体(SNAP和DETA-NO)抑制了DC抗原呈递。正如预期的那样,从癌症患者外周血单核细胞(PBMC)中分离出的MDSC产生了高水平的NO。我们假设荷瘤宿主中产生NO的MDSC会抑制DC抗原呈递。通过[H]-胸苷掺入增殖试验测量DC向CD4 T细胞(T细胞受体转基因OT-II)的抗原呈递。黑色素瘤肿瘤模型中的MDSC比胰腺癌来源的MDSC降低的增殖水平更多。当用诱导型一氧化氮合酶抑制剂(L-NAME和NCX-4016)处理MDSC时,T细胞增殖得以恢复。一种NO供体抑制了OT II T细胞受体对OT II特异性四聚体的识别,从而直接测量了NO对抗原呈递的抑制作用。我们小组之前已经证明,STAT1硝化也介导了MDSC对免疫细胞的抑制作用。因此,一种新型的液相色谱-串联质谱分析法表明,STAT1-Tyr701的硝化发生在胰腺癌和黑色素瘤患者来源的PBMC中。